Combo Therapy Beats Back Relapsed NSCLC

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) with EGFR mutations is often treated with EGFR inhibitors.
• Acquired resistance to EGFR inhibitors, particularly MET-driven resistance, is a significant clinical challenge.

Discussion:

• The TATTON trial's interim analysis suggests a potential benefit of combining osimertinib (EGFR inhibitor) with savolitinib (MET inhibitor).
• This combination therapy addresses MET-driven resistance mechanisms that emerge after treatment with various generations of EGFR inhibitors.

Key Insights:

• Patients with EGFR-mutant NSCLC developing MET-driven resistance can respond to sequential treatment with osimertinib and savolitinib.
• The combination targets both the primary EGFR mutation and secondary MET alterations driving resistance.

Outlook:

• This combination strategy may represent a new therapeutic option for NSCLC patients who have progressed on prior EGFR-targeted therapies.
• Further investigation and long-term data from the TATTON trial are warranted to confirm efficacy and safety.